Company / Free Cash Flow
Akebia Therapeutics, Inc. Free Cash Flow History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$67.7M
FY2025
5-year range
-$264.1M / $67.7M
FY2021-FY2025
Trend
+266.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow changed +266% YoY in FY2025, a notable deviation from the 9-year average annual change of +47%.
Based on SEC 10-K filings.
$68M in FY2025.
Improved from -$23M to $68M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow increased 266.4% year-over-year.
- Lowest free cash flow in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $67.7M | +266.4% |
| FY2024 | -$40.7M | -74.0% |
| FY2023 | -$23.4M | +68.1% |
| FY2022 | -$73.3M | +72.3% |
| FY2021 | -$264.1M | -166.5% |
| FY2020 | -$99.1M | -71.5% |
| FY2019 | -$57.8M | -204.6% |
| FY2018 | $55.2M | +586.7% |
| FY2015 | -$11.4M | -57.0% |
| FY2014 | -$7.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026